Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Poseida Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Poseida Therapeutics's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Poseida Therapeutics (Nasdaq: PSTX) announced the appointment of Rafael G. Amado, M.D., to its Board of Directors on April 13, 2023. Dr. Amado brings extensive expertise in oncology and cell therapies, supporting Poseida's mission to advance innovative treatments for cancer and rare diseases. His leadership roles at Zai Lab, Allogene Therapeutics, and Adaptimmune, along with his background in pharmaceutical research, position him well to provide strategic insights. The CEO, Mark Gergen, welcomed Dr. Amado, emphasizing his potential contribution to the company's growth and the development of its promising pipeline in oncology and genetic diseases. The company focuses on differentiated cell and gene therapies, utilizing proprietary platforms for its product candidates.